Hasbek Zekiye, Turgut Bülent, Erselcan Taner, Koyuncu Ayhan, Fatih Börksüz Mehmet, Turgut Nergiz Hacer, Yumuk Fadime
Cumhuriyet University, School of Medicine, Department of Nuclear Medicine, Sivas, Turkey.
Mol Imaging Radionucl Ther. 2011 Dec;20(3):94-9. doi: 10.4274/MIRT.13. Epub 2011 Dec 1.
In this study, we aimed to evaluate the tumor size for proximal and distant metastases when the new and old TNM classification is taken into account in differentiated thyroid cancers.
Two hundred sixty eight patients diagnosed with thyroid carcinoma, undergoing bilateral total or subtotal thyroidectomy treated with high doses of I-131 were examined retrospectively. The data of these patients were compared after classification, according to tumor size <1 cm and <2 cm, lymph node metastases thyroid and tumor capsule invasion at the time of diagnosis, and accumulation of abnormal activity in post I-131 treatment whole-body scan. I-131 uptakes besides physiological and thyroid bed were considered as abnormal activity uptakes.
A total of 268 patients with average age of 19-82 yrs (mean: 47.0±13.8 yrs) were included in the study. At postoperative histopathological evaluation, 228 (85.1%) of patients were reported as papillary, 13 (4.9%) as follicular, 23 (8.6%) as well differentiated tumor of unknown malignant potential, 2 (0.7%) as insular and 2 (0.7%) as Hürthle-cell carcinoma. In patients with known tumor size, 96 of 207 (46.4%) patients' tumor size was <1 cm and in 111 (53.6%) >1 cm. In the same group, according to the revised TNM classification, in 149 of 207 patients (72%) the tumor size was <2 cm, whereas in 58 (28%) >2 cm. Of 187 patients with negative lymph nodes, 15 (8%) showed abnormal activity accumulation in the first post I-131 treatment whole-body scan and 10 (40% of 25 patients) positive lymph node (p<0.05) involvement.
Since the treatment of patients with microcarcinoma is controversial, tumor size should not be the only factor considered in patients with differentiated thyroid cancer Tissue tumor invasion, age, gender and multifocality should also be taken into account.
None declared.
在本研究中,我们旨在评估在考虑新旧TNM分类的情况下,分化型甲状腺癌近端和远处转移的肿瘤大小。
对268例诊断为甲状腺癌并接受双侧全甲状腺切除术或次全甲状腺切除术且接受高剂量I-131治疗的患者进行回顾性检查。根据诊断时肿瘤大小<1 cm和<2 cm、甲状腺淋巴结转移和肿瘤包膜侵犯情况以及I-131治疗后全身扫描中异常活性的累积情况,对这些患者的数据进行分类后比较。除生理摄取和甲状腺床摄取外的I-131摄取被视为异常活性摄取。
共有268例平均年龄为19 - 82岁(平均:47.0±13.8岁)的患者纳入研究。术后组织病理学评估显示,228例(85.1%)患者为乳头状癌,13例(4.9%)为滤泡状癌,23例(8.6%)为恶性潜能未知的高分化肿瘤,2例(0.7%)为岛状癌,2例(0.7%)为许特莱细胞癌。在已知肿瘤大小的患者中,207例患者中有96例(46.4%)肿瘤大小<1 cm,111例(53.6%)>1 cm。在同一组中,根据修订后的TNM分类,207例患者中有149例(72%)肿瘤大小<2 cm,而58例(28%)>2 cm。在187例淋巴结阴性的患者中,15例(8%)在首次I-131治疗后全身扫描中显示异常活性累积,10例(25例患者中的40%)有阳性淋巴结受累(p<0.05)。
由于微小癌患者的治疗存在争议,肿瘤大小不应是分化型甲状腺癌患者唯一考虑的因素,还应考虑组织肿瘤侵犯、年龄、性别和多灶性。
未声明。